Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.42 |
| ▸ | USP2 | O75604 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20895831 | 1.00 | CCNE2 (0.48) | CCNE2CCNE1CDK2GBA1CYP1A2 | |
| SCHEMBL30013436 | 1.00 | CCNE2 (0.48) | CCNE2CCNE1CDK2GBA1CYP1A2 | |
| SCHEMBL20895830 | 1.00 | CCNE2 (0.48) | CCNE2CCNE1CDK2GBA1CYP1A2 | |
| SCHEMBL30130604 | 1.00 | CCNE2 (0.48) | CCNE2CCNE1CDK2GBA1CYP1A2 | |
| SCHEMBL2317472 | 1.00 | CCNE2 (0.48) | CCNE2CCNE1CDK2GBA1CYP1A2 | |
| SCHEMBL2317462 | 1.00 | CCNE2 (0.48) | CCNE2CCNE1CDK2GBA1CYP1A2 | |
| SCHEMBL30476574 | 1.00 | CCNE2 (0.48) | CCNE2CCNE1CDK2GBA1CYP1A2 | |
| SCHEMBL21240852 | 0.94 | CCNE1 (0.49) | CCNE2CCNE1CDK2GBA1CYP1A2 | |
| SCHEMBL21240851 | 0.94 | CCNE1 (0.49) | CCNE2CCNE1CDK2GBA1CYP1A2 | |
| SCHEMBL2359510 | 0.94 | CCNE1 (0.49) | CCNE2CCNE1CDK2GBA1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210187033-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2021-06-24 | — | — | US | claimed |
| EP-2350078-B1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2019-04-17 | — | — | EP | claimed |
| US-20170239296-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2017-08-24 | — | — | US | claimed |
| US-9580426-B2 | Compounds that expand hematopoietic stem cells | NOVARTIS AG (CH) | 2017-02-28 | — | — | US | claimed |
| US-9175266-B2 | Enhancement of natural killer (NK) cell proliferation and activity | GAMIDA CELL LTD. (IL) | 2015-11-03 | — | — | US | claimed |
| US-8927281-B2 | Method for expanding hematopoietic stem cells | IRM LLC (BM) | 2015-01-06 | — | — | US | claimed |
| US-20140114070-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-24 | — | — | US | claimed |
| US-20140023623-A1 | Methods of Culturing and Expanding Mesenchymal Stem Cells and Isolated Cell Populations Generated Thereby | GAMIDA CELL INC. | 2014-01-23 | — | — | US | claimed |
| US-20140023626-A1 | Enhancement of Natural Killer (NK) Cell Proliferation and Activity | GAMIDA CELL INC. | 2014-01-23 | — | — | US | claimed |
| EP-2350078-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2011-08-03 | — | — | EP | claimed |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-07-22 | — | — | US | claimed |
| WO-2010059401-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-05-27 | — | — | WO | claimed |
| EP-3524604-B1 | EXPANDED HEMATOPOIETIC STEM CELLS FROM CORD BLOOD AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| US-20220401481-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | ENSOMA, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20210379113-A1 | METHODS FOR HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANT THERAPY | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-12-09 | — | — | US | disclosed |
| US-20210187033-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2021-06-24 | — | — | US | disclosed |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| WO-2010059401-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059401-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401481-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | CXCL12, CSF3R, MCL1 | CCNE2 2940/4885CCNE1 2256/4885CDK2 3427/4885 |
| US-20170239296-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | CCNE2 3415/4885CCNE1 3047/4885CDK2 3659/4885 |
| US-20210379113-A1 | METHODS FOR HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANT THERAPY | HCLS1, MPST, THPO | CCNE2 4636/4885CCNE1 4316/4885CDK2 4762/4885 |
| US-20210187033-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | CCNE2 3415/4885CCNE1 3047/4885CDK2 3659/4885 |
| US-20140114070-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | CCNE2 3415/4885CCNE1 3047/4885CDK2 3659/4885 |
| US-20140023626-A1 | Enhancement of Natural Killer (NK) Cell Proliferation and Activity | PBK, IL2, AHR | CCNE2 1316/4885CCNE1 1493/4885CDK2 1909/4885 |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | CCNE2 3415/4885CCNE1 3047/4885CDK2 3659/4885 |
| US-20140023623-A1 | Methods of Culturing and Expanding Mesenchymal Stem Cells and Isolated Cell Populations Generated Thereby | AHR, HGF, MTNR1A | CCNE2 1819/4885CCNE1 2334/4885CDK2 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.